Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.9M | -$26.6M | -$34.9M | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M |
| Net income | -$17.5M | -$25.4M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M |
| EPS (diluted) | -$5.82 | -$8.35 | -$2.40 | -$1.28 | -$1.61 | -$1.44 | -$1.14 | -$1.48 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.2M | -$22.1M | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M |
| Capital expenditures | $452K | $109K | $148K | $1.35M | $7.98M | $962K | $655K | $29.0K |
| Free cash flow | -$15.6M | -$22.2M | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $73.3M | $361M | $172M | $108M | $37.7M | $40.9M | $38.0M |
| Total assets | — | $103M | $366M | $332M | $270M | $252M | $191M | $117M |
| Total liabilities | — | $4.57M | $6.41M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M |
| Shareholders' equity | -$46.1M | -$70.5M | $359M | $309M | $246M | $226M | $176M | $105M |
| Retained earnings | — | -$75.4M | -$110M | -$168M | -$241M | -$310M | -$369M | -$446M |
| Shares (wtd avg diluted) | — | 3.05M | 14.4M | 45.1M | 45.6M | 48.0M | 51.6M | 52.5M |
Every figure is extracted from PMV Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.